ICD-10 Coding for Prostate-Derived Factor(C61.9, C61.9M, C61.9N)
Learn about prostate-derived factor, its role in prostate cancer, and how to document and code it using ICD-10 guidelines.
Complete code families applicable to Prostate-Derived Factor
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C61.9 | Malignant neoplasm of prostate, unspecified | Use when prostate cancer is confirmed and PDF is involved. |
|
| R97.21 | Elevated prostate-specific antigen [PSA] | Use when elevated PSA is documented alongside PDF involvement. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutProstate-Derived Factor
Alternative codes to consider when ruling out similar conditions
Use if PDF overexpression is linked to metastatic spread.
Documentation & Coding Risks
Avoid these common issues when documenting Prostate-Derived Factor.
Omitting PDF's role in documentation
Impact
Clinical: Inaccurate assessment of cancer aggressiveness., Regulatory: Non-compliance with documentation standards., Financial: Potential loss of reimbursement.
Mitigation
Always document PDF levels and role, Use templates for consistency
Coding C61.9 alone for PDF+ tumors
Impact
Reimbursement: Incomplete coding may lead to reduced reimbursement., Compliance: Non-compliance with coding guidelines., Data Quality: Inaccurate data on tumor marker involvement.
Mitigation
Add Z17.8 and 0047U for comprehensive coding.
PDF Documentation
Impact
Lack of quantitative PDF data in records.
Mitigation
Ensure all PDF levels and methods are documented.